Cathie Wood’s AI Vision: Health Care and Software Take Center Stage in 2025
Cathie Wood, the visionary CEO of Ark Invest, isn’t just betting on artificial intelligence (AI) – she’s doubling down on its transformative power, but with an unconventional twist. While the spotlight often shines on flashy applications like self-driving cars, Wood sees the most significant opportunity hidden within healthcare.
"We’ve got 37 trillion cells in our body, and they’re going to be sequenced as we’re looking for cures," Wood articulated during a recent appearance on CNBC’s Squawk Box. "I think the most underappreciated application of AI is healthcare. I think healthcare is responsible for an astounding amount of storage out there right now. Data is the name of the game."
Wood’s conviction in healthcare’s potential is backed by her high-conviction bet on Recursion Pharmaceuticals, a company that has witnessed a tenfold increase in the average number of hypotheses per researcher thanks to AI. Recursion recently received FDA approval to start phase 1 trials of an AI-discovered cancer treatment, a milestone achieved in less than 18 months. This breakthrough underscores the powerful role AI can play in accelerating drug discovery.
Wood’s flagship Ark Innovation ETF (ARKK) holds nearly 19 million shares of Recursion, valued at roughly $140 million. Other healthcare stocks in ARKK include Crispr Therapeutics, Tempus AI, Twist Bioscience, and Beam Therapeutics, all poised to benefit from AI-driven advancements.
While healthcare is Wood’s long-term focus, she also sees robotaxis as the biggest AI application in the next five to ten years, with Tesla as the top enabler. However, her investment strategy is shifting away from hardware and infrastructure toward software.
One of her top software picks is Palantir, which recently reported stronger-than-expected fourth-quarter results driven by AI. “Palantir is a very expensive stock, but there’s nothing like it in the software space,” Wood stated. “It is indeed, we believe, going to dominate the biggest part of the tech stack when it comes to AI. And that’s the platform-as-a-service part of the stack.”
Palantir’s shares surged 24% to a record high following the earnings report, with CEO Alex Karp describing the momentum in its commercial and government segments as “unlike anything that has come before.”
Key Takeaways: Cathie Wood’s AI Investment Strategy
| Focus Area | Key Players | Highlights |
| ————————– | ——————————— | —————————————————————————————————————————————————— |
| Health Care | Recursion Pharmaceuticals | FDA approval for AI-discovered cancer treatment; 9% stock gain in 2025 |
| Software | Palantir | Record-high stock surge; dominance in AI platform-as-a-service |
| Robotaxis | Tesla | Enabler of the next big AI application in the next 5-10 years |
Wood’s insights highlight the transformative potential of AI across industries, with healthcare and software leading the charge. As she continues to bet on innovation, investors are watching closely to see how these trends unfold in the coming years.